Indaptus Therapeutics, Inc.
INDP
$2.57
$0.4923.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.86% | -5.29% | 213.93% | -32.53% | -4.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.41% | -52.77% | 95.51% | -15.71% | 8.47% |
| Operating Income | 59.41% | 52.77% | -95.51% | 15.71% | -8.47% |
| Income Before Tax | 65.67% | 43.93% | -96.38% | 3.06% | -30.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.67% | 43.93% | -96.38% | 3.06% | -30.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.67% | 43.93% | -96.38% | 3.06% | -30.22% |
| EBIT | 59.41% | 52.77% | -95.51% | 15.71% | -8.47% |
| EBITDA | -- | -- | -95.50% | 15.72% | -8.46% |
| EPS Basic | 99.83% | 97.45% | 57.36% | 66.98% | 30.88% |
| Normalized Basic EPS | 99.83% | 97.45% | 57.36% | 66.98% | 30.88% |
| EPS Diluted | 99.83% | 97.45% | 57.36% | 66.98% | 30.88% |
| Normalized Diluted EPS | 99.83% | 97.45% | 57.36% | 66.98% | 30.88% |
| Average Basic Shares Outstanding | 20,100.24% | 2,101.02% | 360.53% | 193.49% | 88.43% |
| Average Diluted Shares Outstanding | 20,100.24% | 2,101.02% | 360.53% | 193.49% | 88.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |